期刊
RADIOLOGY
卷 284, 期 3, 页码 616-629出版社
RADIOLOGICAL SOC NORTH AMERICA
DOI: 10.1148/radiol.2017162759
关键词
-
资金
- Eunice Kennedy Shriver National Institute of Child Health and Human Development [5HD081123]
- National Cancer Institute [R21CA190196, R21CA176519]
- National Institute of Arthritis and Musculoskeletal and Skin Diseases [4R01AR054458-09, R21AR066302]
Amid mounting concerns about nephrogenic sclerosis and gadolinium deposition in the brain, physicians and patients alike are starting to question the use of gadolinium chelates for clinical magnetic resonance (MR) imaging. The search for safer alternatives is currently underway. In North America, the iron supplement ferumoxytol has gained considerable interest as an MR contrast agent. In Europe, ferumoxtran-10 is entering phase III clinical trials. As these agents are starting to be used by a new generation of radiologists, important clinical questions have re-emerged, including those that have been answered in the past. This article offers 10 important insights for the use of iron oxide nanoparticles in clinical MR imaging. Published under a CC BY-NC-ND 4.0 license.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据